studies

metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2), combined BRAF-MEK inhibitors vs. docetaxel, meta-analysis of study results

No data for this selection

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 197,255,37,245,204,244,241,227,217,177,279,167,1,170,261,280,168,169 - treatments: 423,424,425,562,426